<SEC-DOCUMENT>0001193125-12-497123.txt : 20121210
<SEC-HEADER>0001193125-12-497123.hdr.sgml : 20121210
<ACCEPTANCE-DATETIME>20121210171333
ACCESSION NUMBER:		0001193125-12-497123
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20121205
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20121210
DATE AS OF CHANGE:		20121210

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			DELCATH SYSTEMS INC
		CENTRAL INDEX KEY:			0000872912
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				061245881
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-16133
		FILM NUMBER:		121254005

	BUSINESS ADDRESS:	
		STREET 1:		810 SEVENTH AVENUE
		STREET 2:		FL 35
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019
		BUSINESS PHONE:		212-489-2100

	MAIL ADDRESS:	
		STREET 1:		810 SEVENTH AVENUE
		STREET 2:		FL 35
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d451575d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>WASHINGTON, D.C. 20549 </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM 8-K
</B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>CURRENT REPORT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>PURSUANT TO SECTION 13 OR 15(D) OF THE </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>SECURITIES EXCHANGE ACT OF 1934
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Date of report (Date of earliest event reported): December&nbsp;10, 2012 (December 5, 2012) </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>DELCATH SYSTEMS, INC. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact name of registrant as specified in its charter) </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>001-16133</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>06-1245881</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or Other Jurisdiction</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>of Incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Commission</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>File Number)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(IRS Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification Number)</B></FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:0px; " ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>810 Seventh Avenue, 35<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">th</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> Floor, New York, New York, 10019 </FONT></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of principal executive offices, including zip code) </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(212)
489-2100 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Registrant&#146;s telephone number, including area code) </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NONE </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Former name or former address, if changed since last report) </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.
below): </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;7.01. Regulation FD Disclosure. </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On December&nbsp;5, 2012 Delcath Systems, Inc. (the &#147;Company&#148;) hosted a webinar to discuss the Company&#146;s recent corporate
developments. A copy of the transcript of the webinar is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated into this Item&nbsp;7.01 by reference. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The information disclosed under this Item&nbsp;7.01, including Exhibit 99.1 hereto, is being furnished and shall not be deemed &#147;filed&#148; for purposes of Section&nbsp;18 of the Securities Exchange
Act of 1934, as amended, nor shall it be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, except as expressly set forth in such filing. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;9.01. Financial Statements and Exhibits. </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following exhibit is filed herewith: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d)
Exhibits. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:25pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit<BR>No.</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:39pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Delcath Systems, Inc. Webinar Transcript</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD></TR>


<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">DELCATH SYSTEMS, INC.</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dated: December&nbsp;10, 2012</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Peter J. Graham</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Peter J. Graham</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Executive Vice President,</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">General Counsel</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXHIBIT INDEX </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit<BR>No.</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Delcath Systems, Inc. Webinar Transcript</FONT></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d451575dex991.htm
<DESCRIPTION>DELCATH SYSTEMS, INC. WEBINAR TRANSCRIPT
<TEXT>
<HTML><HEAD>
<TITLE>Delcath Systems, Inc. Webinar Transcript</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">THOMSON REUTERS STREETEVENTS </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EDITED TRANSCRIPT </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">DCTH - Delcath Corporate Update Webinar </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">EVENT
DATE/TIME: DECEMBER 05, 2012 / 10:00PM GMT </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1 </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="28%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">THOMSON REUTERS STREETEVENTS | <U>www.streetevents.com</U> | <U>Contact Us</U></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ROWSPAN="2" ALIGN="right">


<IMG SRC="g451575ex99_1footer.jpg" ALT="LOGO">
</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&copy; 2012 Thomson Reuters. All rights reserved. Republication or
redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. &#145;Thomson Reuters&#146; and the Thomson Reuters logo are registered trademarks of Thomson
Reuters and its affiliated companies.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">DECEMBER 05, 2012 / 10:00PM GMT, DCTH - Delcath Corporate Update Webinar </FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CORPORATE PARTICIPANTS </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Gregory Gin </B><I>EVC Group - IR</I><B> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Eamonn Hobbs </B><I>Delcath Systems Inc -
President&nbsp;&amp; CEO</I><B> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Graham Miao </B><I>Delcath Systems Inc - EVP&nbsp;&amp; CFO</I><B> </B></FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PRESENTATION </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Operator </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Good afternoon, ladies and gentlemen, and welcome to the Delcath corporate update. At this time, all participants are in a listen-only mode and will
remain so for the duration of today&#146;s conference. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">(Operator Instructions) </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Please note that this conference is being recorded. I would now like to turn the call over to Mr.&nbsp;Gregory Gin of EVC Group. Please, go ahead. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I></I></B><B>Gregory Gin</B><B><I> - EVC Group - IR </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Thank you, Operator; and good
afternoon, everyone. Thank you for joining us for this webinar to provide an update on Delcath&#146;s recent corporate progress. An archived replay of the webinar will available approximately two hours after its conclusion, and it will be available
for seven days on the Company&#146;s website at www.delcath.com. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Before we begin, I would like to remind you that some of the statements made
during this webinar will contain forward-looking statements within the meaning of the Safe Harbor provision of the US Private Securities Litigation Reform Act of 1995. These statements are subject to certain risks and uncertainties and actual
results could differ materially from those projected in any forward-looking statements. Factors that could cause actual results to differ are discussed from time to time in the Company&#146;s filings with the SEC, including our Annual Report on Form
10-K and our reports on Form 10-Q and 8-K. These documents are available on the Investor Relations section of our website and we encourage you to review the material. The Company has no obligation to publicly update or revise these forward-looking
statements to reflect the events or circumstances after the date they are made. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Participating in today&#146;s webinar are Eamonn Hobbs,
President and Chief Executive Officer; and Graham Miao, Executive Vice President and Chief Financial Officer. Following their opening remarks, there will be in question-and-answer period. Questions can be submitted electronically via the webinar
interface, and questions will be summarized and addressed. Feel free to forward us your questions during the course of this webinar and we will summarize and address them at the end. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Now, I&#146;d like to turn the call over to Mr.&nbsp;Hobbs. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I></I></B><B>Eamonn Hobbs</B><B><I> - Delcath
Systems Inc - President&nbsp;&amp; CEO </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Thank you, and good afternoon, everyone. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The purpose of today&#146;s webinar is to review the news we announced this afternoon after the market closed regarding our committed equity facility and
modification of our new drug application, or NDA, pending with the US FDA, as well to provide a brief update on other recent corporate developments. I will start with the NDA and other developments, and then turn it over to Graham to discuss the
committed equity financing vehicle. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Let&#146;s begin. We have had recent discussions with the FDA and are very appreciative of the FDA&#146;s
interest in our NDA and the progress that has been made to date towards our June PDUFA goal date. Although the Company&#146;s Phase 3 trial demonstrated a very positive signal in patients with unresectable liver dominant cutaneous melanoma, based on
the Agency&#146;s recommendation, we have decided to focus our NDA&#146;s indication for the treatment of patients with unresectable metastatic ocular melanoma in the liver. This is due to 90% of the patients enrolled in our Phase 3 trial having
ocular melanoma metastases to the liver and the statistically significant efficacy data generated in the trial for this disease. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2 </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="28%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">THOMSON REUTERS STREETEVENTS | <U>www.streetevents.com</U> | <U>Contact Us</U></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ROWSPAN="2" ALIGN="right">


<IMG SRC="g451575ex99_1footer.jpg" ALT="LOGO">
</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&copy; 2012 Thomson Reuters. All rights reserved. Republication or
redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. &#145;Thomson Reuters&#146; and the Thomson Reuters logo are registered trademarks of Thomson
Reuters and its affiliated companies.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">DECEMBER 05, 2012 / 10:00PM GMT, DCTH - Delcath Corporate Update Webinar </FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Additionally, FDA-approved treatment options have evolved significantly for metastatic cutaneous
melanoma over the past several years, while treatment options for unresectable metastatic ocular melanoma continue to be lacking. This evolution, since our SPA was approved, has raised the regulatory bar for new drug approvals for treatment of
cutaneous melanoma considerably. Given these facts, we believe that our data in metastatic ocular melanoma, coupled with the large unmet need for treatments in this disease, presents the most compelling case for our NDA, and the best opportunity for
FDA approval of our chemosaturation system. We hope that a timely approval of our chemosaturation system will represent an important step to bring benefits to those cancer patients afflicted with this disease. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">It is important to note that the modification of the indication in our NDA submission has not impacted our June PDUFA goal date. Remember that the FDA
previously granted orphan-drug designation for melphalan in ocular melanoma, so assuming our NDA is approved, orphan-drug designation will provide Delcath with seven years of marketing exclusivity in this indication. Additionally, assuming our NDA
is approved, we believe the decision to focus the initial labeling for our proprietary chemosaturation system on ocular melanoma will have little impact on our revenue potential in the United States. We believe that this is due to the fact that
physicians in the United States typically prescribe any cancer treatment option based on clinical data and their professional medical experience. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">While we are changing our request for labeled indication, the clinical data associated with our therapy remains the same and will continue to grow as we conduct further clinical trials. To that end, we
plan to initiate clinical studies in 2013 to study the use of our chemosaturation system in other tumor types that potentially represent significant commercial opportunities beyond the ocular metastatic melanoma market. Currently, we intend to
pursue studies to support label expansion for the use of our system to treat hepatocellular carcinoma and neuroendocrine cancer patients, and depending on feedback from the FDA, could potentially enroll our first patients before the end of 2013.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Before turning the call over to Graham, I&#146;d now like to provide a brief update on the European launch of CHEMOSAT, where we are making
steady progress. Physicians in Europe continue to treat patients with liver dominant metastases from a variety of tumor types, including both cutaneous and ocular melanoma, gastric cancer, breast cancer, and cholangiocarcinoma. We also have begun to
see first patients with HCC, or primary liver cancer, and NET neuroendocrine tumors treated with CHEMOSAT in the European Union. We believe this illustrates how clinical data and professional medical experience drives usage of new therapies, as well
as the broad potential that physicians see in using chemosaturation therapy to help patients suffering from wide varieties of cancers in the liver. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In early November, we reported the first national reimbursement mechanism for CHEMOSAT procedures in Europe under an existing Italian diagnostic-related group code, or DRG code. Establishing reimbursement
across our targeted EU markets is critical to our commercialization efforts, and we are pursuing additional supplemental new technology payment programs in Italy, as well as conducting a concentrated effort to establish reimbursement in Germany and
the UK, where we hope to receive positive reimbursement determinations in the first quarter of next year. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">In Germany, a new cancer center at
Gottingen University successfully performed its first CHEMOSAT procedure last week, bringing us to seven CHEMOSAT-trained launch centers in Europe so far this year. Gottingen University has also submitted a reimbursement application to a major
private insurance carrier in Germany and received reimbursement. This is an interim mechanism we will attempt to leverage elsewhere in Germany until an expected decision by the NUB is rendered in the first quarter next year. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Also, we intend to build clinical experience with CHEMOSAT through investigator-initiated clinical trials by leading EU opinion leaders in tumor types
where there is a large need. We believe these small trials will help build a growing body of evidence to support the clinical case for CHEMOSAT and help drive clinical adoption at key centers, which we hope will facilitate wider usage, once
reimbursement mechanisms become available. In addition, these studies, if positive, will provide support of data for future US-registration trials in indications with a large need. Together with our reimbursement efforts, and with additional centers
coming online in the next few weeks, we are building momentum for growth in Europe during 2013. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">With that, I would like to have Graham Miao
provide a review of the committed equity financing facility that we announced this afternoon, and then we will take questions. Graham? </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I></I></B><B>Graham Miao</B><B><I> - Delcath
Systems Inc - EVP&nbsp;&amp; CFO </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Thank you, Eamonn. Good afternoon, everyone. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">As part of our ongoing efforts to strengthen our balance sheet, we have established a committed equity financing facility, or CEFF, under which we may
sell up to $35 million of our registered common stock to Terrapin Opportunity Fund over a 24-month period. This CEFF is a common financing resource that has been successfully used by late-stage development biotechnology companies. The new facility
provides Delcath with the ability to potentially raise capital more efficiently by issuing shares at the time of our choosing. When, and if, we elect to use the facility, a modest discount would be applied to the purchase price, ranging between 3.6%
and 5.8% to the volume weighted average price of Delcath&#146;s common stock over a preceding period of trading days. We are not obliged to utilize any of the $35 million facility, and we are free to enter into other equity and debt financing
transactions, subject to certain restrictions. It is important to emphasize that no warrants are associated with this committed equity financing facility. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3 </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="28%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">THOMSON REUTERS STREETEVENTS | <U>www.streetevents.com</U> | <U>Contact Us</U></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ROWSPAN="2" ALIGN="right">


<IMG SRC="g451575ex99_1footer.jpg" ALT="LOGO">
</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&copy; 2012 Thomson Reuters. All rights reserved. Republication or
redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. &#145;Thomson Reuters&#146; and the Thomson Reuters logo are registered trademarks of Thomson
Reuters and its affiliated companies.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">DECEMBER 05, 2012 / 10:00PM GMT, DCTH - Delcath Corporate Update Webinar </FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">As you may know, in late December of last year, we established an At-The-Market, or ATM, financing
program to sell up to $40 million in shares of our common stock from time to time. This new CEFF differs from the ATM by providing Delcath the ability to raise a larger amount of capital at one time as compared to the ATM. The CEFF also enables the
Company to know where the shares are being held initially. In the Terrapin Fund, the investor has a successful track record with investments in the life sciences space. At the same time, the equity financing facility offers certain advantages over
other financing strategies, including the ability to raise capital quickly, at a competitive cost, and it may allow us to manage dilution more effectively by issuing shares in multiple tranches at times of our choosing over the next 24 months.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">This flexible financing facility is an important component of our portfolio of financing options. Combined with our $28 million in cash on
hand at September&nbsp;30, 2012, and an additional $21.5 million currently available under our At-The-Market program, we believe that the CEFF provides our Company with additional resources and flexibility required to execute our operation plan
through our June&nbsp;15, 2013 PDUFA goal date and well beyond. We continue to expect our average monthly cash expenses of $3 million to $4 million in the fourth quarter and anticipate maintaining this level in 2013. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">That concludes our prepared remarks. We will be happy to take your questions online. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>QUESTION AND ANSWER </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Gregory Gin - </B><B><I>EVC Group</I></B><B> -
</B><B><I>IR</I></B><B> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Thank you, Graham. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">As a reminder, questions can be submitted electronically via the webinar interface, and questions will be summarized and addressed. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(Caller Instructions) </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The first question is &#151; why did you choose to modify the label
indication? Actually, this first questioner has two questions. The second question is &#151; won&#146;t this narrower indication diminish the sales opportunity? </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I></I></B><B>Eamonn Hobbs</B><B><I> - Delcath
Systems Inc - President&nbsp;&amp; CEO </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Thanks, Greg. I&#146;ll take a shot at that. Although our Phase 3 trial demonstrated a very
positive signal in patients with unresectable liver dominant cutaneous melanoma, based on the FDA&#146;s recommendation, we have decided to focus our NDA&#146;s indication solely for the treatment of patients with unresectable metastatic ocular
melanoma in the liver. As we mentioned earlier, this is due to the fact that our data is strongest in ocular melanoma, in that 90% of the patients in our Phase 3 trial were ocular melanoma patients, and the data is most compelling in that area.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Additionally, and very importantly, the world moved on during the course of the seven-plus years since the SPA was negotiated and approved by
the FDA. When the SPA was agreed to with the FDA back in 2005, there were no treatments approved by the FDA for melanoma metastases of any kind, including cutaneous and ocular. So, the trial that was conducted by the Company agreed to under the SPA,
really did not &#151; was not designed to provide discrete data for each type, and the two types of melanoma were grouped together. I was not there at the time in 2005, but I would suggest that if I had been there I might have believed that there
was no preassumption that there was any difference between how melanoma would react in the liver to a treatment, regardless of where it came from. And in fact, that still permeates the clinical mindset that melanoma is melanoma with regard to a
cytotoxic agent in the liver. Since that time, multiple drugs have been approved by FDA to treat cutaneous melanoma, and the bar has risen significantly for what FDA is going to require to get a new &#151; an additional cutaneous melanoma product
approved and labeled for that. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ocular, on the other hand, has not progressed. There are still no FDA-approved treatments for unresectable
ocular melanoma, and none of the existing therapies has shown &#151; has demonstrated benefit, to our knowledge. So, there is nothing existing, and apparently nothing in the pipeline for ocular melanoma, so the bar still pretty much where it was in
2005. Combining these two things &#151; our data being extremely strong in ocular melanoma and the fact that the regulatory bar for approval in cutaneous melanoma has risen significantly, we were not surprised, I have to say, when FDA said &#151;
agreed, this is what we agreed to long ago, but the world has moved on, and we think &#151; FDA told us in a recommendation, we think that you should focus your indication on ocular because there is still a very large unmet need there for these
patients and you&#146;ve shown significant benefit. That answers the question with regard to why we chose to limit the label. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4 </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="28%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">THOMSON REUTERS STREETEVENTS | <U>www.streetevents.com</U> | <U>Contact Us</U></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ROWSPAN="2" ALIGN="right">


<IMG SRC="g451575ex99_1footer.jpg" ALT="LOGO">
</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&copy; 2012 Thomson Reuters. All rights reserved. Republication or
redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. &#145;Thomson Reuters&#146; and the Thomson Reuters logo are registered trademarks of Thomson
Reuters and its affiliated companies.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">DECEMBER 05, 2012 / 10:00PM GMT, DCTH - Delcath Corporate Update Webinar </FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The second part of the question about the diminished sales opportunity is really best answered by
differentiating between label and clinical use. In oncology, clinicians choose therapies based on clinical data that supports the therapy, medical judgment, and very rarely does the label come into it. A label is extraordinarily important to provide
access for clinicians to choose the medicines and therapies they are going to use, but the practice of medicine is not driven, by any extent, solely by labeling. We believe that the data has not changed. We are very comfortable in that. Regardless
of what we do to our label, clinicians are going to use it in the way that they see fit as they were before. So, we do not believe this is going to reflect a change in our revenue opportunity going forward in the United States. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Last but not least, I&#146;d point out that in Europe, we aren&#146;t seeing ocular melanoma drive the procedures. Certainly, ocular melanoma mets
patients are being treated, but they are not dominating the patient mix. There are plenty of cutaneous patients being treated as well as HCC patients, neuroendocrine patients, gastric cancer patients, breast cancer patients, gallbladder cancer
patients, cholangiocarcinomas, et cetera. So, we are seeing a very broad clinical adoption, and I think that speaks very loudly in how clinicians choose their therapies. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I></I></B><B>Gregory Gin</B><B><I> - EVC Group - IR </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Thank you. The next question is
&#151; based on the CEFF financing, do you think you will have to sell more stock before you are profitable? </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I></I></B><B>Graham Miao</B><B><I> - Delcath
Systems Inc - EVP&nbsp;&amp; CFO </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Let me address that. With this recent financing, we would have approximately over $80 million in
available resources. Particularly based on the strong momentum we are seeing now in Europe and the prospect of entering the US market in 2013, we believe that the committed equity financing facility, along with ATM together with our cash on hand,
provides us with the resources needed to execute our plan and cash expenses between $3 million to $4 million average per month through our June PDUFA goal date and well beyond. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I></I></B><B>Gregory Gin</B><B><I> - EVC Group - IR </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Okay. The next question is &#151;
is Delcath charging for its EAP program, and how many cases &#151; can you provide an update on number of cases? </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I></I></B><B>Eamonn Hobbs</B><B><I> - Delcath
Systems Inc - President&nbsp;&amp; CEO </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The EAP program has yet to conduct a procedure on a patient. We are very close. One of the
sites is actively looking to schedule a patient, so we are hopeful that they will this month. Other sites are in various stages of getting their local Institutional Review Board, their IRB, sign offs, and I think it is more likely that they will
enroll patients and conduct procedures on them in, if we get lucky, late December, but with the holidays that may get in the way, and early January. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">With regard to charging, we are still studying the opportunities to do that, and there is no question we would desire to do so, but we are using the EAP &#151; we don&#146;t want to slow the EAP down,
that&#146;s the best way to characterize it. And, since our PDUFA date is six months away, a little over six months away, a few weeks past that, it&#146;s pretty imminent, so we want to make sure the EAP gets going as quickly as possible, and if
charging for the supplies slows that down, it becomes hugely problematic. That is where we are. We really don&#146;t have a hard-and-fast answer quite yet. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I></I></B><B>Gregory Gin</B><B><I> - EVC Group
- IR </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The next question is &#151; can you provide an update on the potential regulatory approvals in ex-US, specifically Hong Kong and
Canada? </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I></I></B><B>Eamonn Hobbs</B><B><I> - Delcath Systems Inc - President&nbsp;&amp; CEO </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">In Hong Kong, we have regulatory approval for the Gen 1 and have Gen 2 regulatory approval pending, and we expect that any time. In Canada, we are in
active &#151; under active review and have routine interactions with the regulatory authorities there, so that is moving along very well &#151; very hard to put a date on when their review will be completed. There is no statutory time limit, but we
think they are in the near term, not the far term. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5 </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="28%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">THOMSON REUTERS STREETEVENTS | <U>www.streetevents.com</U> | <U>Contact Us</U></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ROWSPAN="2" ALIGN="right">


<IMG SRC="g451575ex99_1footer.jpg" ALT="LOGO">
</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&copy; 2012 Thomson Reuters. All rights reserved. Republication or
redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. &#145;Thomson Reuters&#146; and the Thomson Reuters logo are registered trademarks of Thomson
Reuters and its affiliated companies.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">DECEMBER 05, 2012 / 10:00PM GMT, DCTH - Delcath Corporate Update Webinar </FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Gregory Gin </B><B><I>- </I></B><I></I><B><I>EVC Group - IR</I></B><I></I><B><I></I></B><B> </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Next question is &#151; can you provide an update on the entry into the Australian market? </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Eamonn Hobbs </B><B><I>- Delcath Systems Inc - President&nbsp;&amp; CEO</I></B><B> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are
very close to signing a distributor in Australia and New Zealand. We are fully approved there with Gen 2 and have been negotiating with a number of distributors and are down to the final negotiations now, so I would expect we will have a distributor
signed up in Q1. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Gregory Gin </B><B><I>- EVC Group - IR</I></B><B> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The next question is &#151; in terms of
using the ATM program going forward, do you anticipate suspending it given the CEFF financing program? </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Graham Miao </B><B><I>- Delcath Systems Inc -
EVP&nbsp;&amp; CFO</I></B><B> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">We believe both CEFF, certainly CEFF and ATM offers different features, and we believe they can coexist
concurrently. Particularly now, we see certain advantages of a committed equity facility. So, once that is in place and depending on market conditions, we will utilize the CEFF because it does offer a larger amount at one time and the competitive
price cost and also directly with an investor, but regardless, ATM will coexist until the program expires. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Eamonn Hobbs </B><B><I>- Delcath Systems Inc -
President&nbsp;&amp; CEO</I></B><B> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">I would just add to that, echoing what Graham just mentioned, that both programs have their pluses and
minuses, and we will use them to the advantage of the Company. Added together, along with our current cash on hand, we have ample funding to get us through PDUFA date, as Graham has mentioned. It is unlikely we will be using them at the exact same
time. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Gregory Gin </B><B><I>- EVC Group - IR</I></B><B> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The next question is &#151; what is the
population of patients in United States with unresectable metastatic ocular melanoma? </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Eamonn Hobbs </B><B><I>- Delcath Systems Inc -
President&nbsp;&amp; CEO</I></B><B> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The population of patients that are idealized for our therapy, based on a number of estimates both
internal and external, is approximately 1,700. With each of them requiring, on average, 2.5 procedures for a treatment course, and the patients in the Phase 3 received 3 treatments, that brings it out to 4,200 treatments for ocular melanoma. Once
again, I would stress that that would be a fraction of how our product&#146;s being used in Europe, currently. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Gregory Gin </B><B><I>- EVC Group -
IR</I></B><B> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The next question has to do with the FDA review &#151; are we still expecting FDA-panel review before June of 2013?
</FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Eamonn Hobbs </B><B><I>- Delcath Systems Inc - President&nbsp;&amp; CEO</I></B><B> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Are we
expecting an FDA review? </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Gregory Gin </B><B><I>- EVC Group - IR</I></B><B> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Panel review &#151; </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6 </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="28%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">THOMSON REUTERS STREETEVENTS | <U>www.streetevents.com</U> | <U>Contact Us</U></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ROWSPAN="2" ALIGN="right">


<IMG SRC="g451575ex99_1footer.jpg" ALT="LOGO">
</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&copy; 2012 Thomson Reuters. All rights reserved. Republication or
redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. &#145;Thomson Reuters&#146; and the Thomson Reuters logo are registered trademarks of Thomson
Reuters and its affiliated companies.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">DECEMBER 05, 2012 / 10:00PM GMT, DCTH - Delcath Corporate Update Webinar </FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I></I></B><B>Eamonn Hobbs</B><B><I> - Delcath Systems Inc - President&nbsp;&amp; CEO </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Panel, excuse me &#151; an ODAC panel review. Yes, FDA has advised us to expect an ODAC panel in May. So, the schedule for next year has yet to be set, and we asked them, because we are actively
preparing, to narrow that down for us, and they said it was unlikely it was going to be in the February ODAC and the, potentially, the next one would be May. So, that is what we know so far. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I></I></B><B>Gregory Gin</B><B><I> - EVC Group - IR </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The next question is &#151; if
approved by the FDA, what are your plans for reimbursement for the chemosaturation system in the United States? </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I></I></B><B>Eamonn Hobbs </B><B><I>- Delcath
Systems Inc - President&nbsp;&amp; CEO </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have an active program underway to create new codes, category-one codes, for our procedure.
We are soliciting the support of various medical professional societies, which is all a normal part of pursuing new codes. In the interim, while those codes are being pursued, we would pursue unspecified codes, via negotiation with the insurance
companies, so an interim reimbursement program not unlike what we are pursuing in Europe. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The good news with the United States compared to
Europe, is Europe is an extremely fractionated continent that has independent, very independent-thinking reimbursement authorities across the continent, and each one has to be pursued in parallel, where in the US it is much more consolidated to the
one system. The good news on US reimbursement is we have had compassionate-use patients that have been paid for by private insurance, and we take that as a very positive sign. That was negotiated between the treating centers and the private
insurance that covered those patients that were receiving compassionate use. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I></I></B><B>Gregory Gin</B><B><I> - EVC Group
- IR </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The next question is &#151; what do you estimate to be the revenue opportunity in the US annually for ocular metastatic melanoma?
</FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I></I></B><B>Eamonn Hobbs</B><B><I> - Delcath Systems Inc - President&nbsp;&amp; CEO </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">We estimate the annual revenue opportunity, based on approximately 1,700 patients, to be approximately $105 million for ocular metastatic melanoma
treatments. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I></I></B><B>Gregory Gin</B><B><I> - EVC Group - IR </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The next question comes &#151;
how do you anticipate that the changes to the label that you are seeking for your NDA filing will impact the PDUFA date? And, this questioner has a second question &#151; will this result in a delay? </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I></I></B><B>Eamonn Hobbs</B> <B><I>- Delcath Systems Inc - President&nbsp;&amp; CEO </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">We don&#146;t anticipate any delay whatsoever. We are always hopeful of an earlier FDA decision that&#146;s positive, but there is no impact on the
indication change with regard to changing the PDUFA date to the negative. FDA, it sets a PDUFA date as a goal that they always try and beat, and I&#146;m sure if they feel they have opportunities to complete their review earlier than the PDUFA date,
they will do that. They have done that recently on a number of other oncology drugs, but we certainly have nothing other than crossed fingers and hope that that would happen. Right now, we are still assuming that we are on a timeline to the
June&nbsp;15, certainly no delays &#151; no hint of delays has come up so far. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I></I></B><B>Gregory Gin</B><B><I> - EVC Group
- IR </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The next question is &#151; based on interactions with the FDA, do you still expect the Gen 2 filter to be included in the
potential June approval? </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7 </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="28%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">THOMSON REUTERS STREETEVENTS | <U>www.streetevents.com</U> | <U>Contact Us</U></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ROWSPAN="2" ALIGN="right">


<IMG SRC="g451575ex99_1footer.jpg" ALT="LOGO">
</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&copy; 2012 Thomson Reuters. All rights reserved. Republication or
redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. &#145;Thomson Reuters&#146; and the Thomson Reuters logo are registered trademarks of Thomson
Reuters and its affiliated companies.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">DECEMBER 05, 2012 / 10:00PM GMT, DCTH - Delcath Corporate Update Webinar </FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I></I></B><B>Eamonn Hobbs</B><B><I> - Delcath Systems Inc - President&nbsp;&amp; CEO </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Yes, we do. We have had substantive and multiple substantive review interactions concerning Gen 2, and so far, so good. It is progressing through the review process as a technical change to the CMC module
as an improvement in a Gen 1 filter, which it is. So, so far, so good. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Gregory Gin - </B><B><I>EVC Group -
IR</I></B><B> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have received a number of questions to ask for an update on potential partnerships. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Eamonn Hobbs - </B><B><I>Delcath Systems Inc - President&nbsp;&amp; CEO</I></B><B> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are
actively involved in a number of potential partnership negotiations. We really don&#146;t have anything to report today, other than we are very actively involved, and we have focused resources on bringing those deals to &#151; those partnerships to
fruition, but really don&#146;t have any further comment on those today. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Gregory Gin - </B><B><I>EVC Group -
IR</I></B><B> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The next question comes with respect to the clinical trial programs under consideration &#151; is there an investigation of
chemosaturation with lung cancer? </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I></I></B><B>Eamonn Hobbs</B><B><I> - Delcath Systems Inc - President&nbsp;&amp; CEO </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">There is, we have a development program that is in the early stages to isolate the lung for primary lung cancer, and also to isolate the brain for primary brain cancer. We, to my knowledge, have not
treated a liver-mets patient that had the primary be lung cancer. To my memory, I do not believe we have done that. But, if the question is referring to primary lung cancer in going after that, we are pursuing a development program to do that.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">I would point out that it isn&#146;t that far down the road, with regard to concept anyway, because surgeons have done isolated lung
perfusions with melphalan to validate the concept works. And of course, the surgical procedure is extremely complex and challenging for the patients, so a percutaneous way of doing that is being received very, very enthusiastically by the surgical
community as potentially opening up a whole new way of treating primary lung cancer patients, so we are very excited about that. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I></I></B><B>Gregory Gin</B> <B><I>- EVC Group
- IR </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">With that, Eamonn, that is all the time that we have for questions. I will turn it over to you for any closing remarks.
</FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I></I></B><B>Eamonn Hobbs</B><B><I> - Delcath Systems Inc - President&nbsp;&amp; CEO </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Thanks, Greg. I&#146;d like to thank everyone for participating in today&#146;s webinar. We are finishing the year with solid momentum in Europe, the real
prospect of entering the US market during 2013, and in a strong financial position with approximately $80 million in available resources. Delcath has never been better positioned to generate returns for shareholders, and that is one of our key goals
for the year ahead. We look forward to updating you on further progress. Thanks very much, everybody. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Operator </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Thank you. Thank you, ladies and gentlemen. This concludes today&#146;s conference. Thank you for participating. You may all disconnect. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8 </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="28%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">THOMSON REUTERS STREETEVENTS | <U>www.streetevents.com</U> | <U>Contact Us</U></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ROWSPAN="2" ALIGN="right">


<IMG SRC="g451575ex99_1footer.jpg" ALT="LOGO">
</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&copy; 2012 Thomson Reuters. All rights reserved. Republication or
redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. &#145;Thomson Reuters&#146; and the Thomson Reuters logo are registered trademarks of Thomson
Reuters and its affiliated companies.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">DECEMBER 05, 2012 / 10:00PM GMT, DCTH - Delcath Corporate Update Webinar </FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>DISCLAIMER </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Thomson Reuters reserves the right to make changes to documents, content, or other information on this web site without obligation to notify any person of such changes. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the conference calls upon which Event Transcripts are based, companies may make projections or other forward-looking statements regarding a variety of
items. Such forward-looking statements are based upon current expectations and involve risks and uncertainties. Actual results may differ materially from those stated in any forward-looking statement based on a number of important factors and risks,
which are more specifically identified in the companies&#146; most recent SEC filings. Although the companies may indicate and believe that the assumptions underlying the forward-looking statements are reasonable, any of the assumptions could prove
inaccurate or incorrect and, therefore, there can be no assurance that the results contemplated in the forward-looking statements will be realized. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">THE INFORMATION CONTAINED IN EVENT TRANSCRIPTS IS A TEXTUAL REPRESENTATION OF THE APPLICABLE COMPANY&#146;S CONFERENCE CALL AND WHILE EFFORTS ARE MADE TO PROVIDE AN ACCURATE TRANSCRIPTION, THERE MAY BE
MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORTING OF THE SUBSTANCE OF THE CONFERENCE CALLS. IN NO WAY DOES THOMSON REUTERS OR THE APPLICABLE COMPANY ASSUME ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE
INFORMATION PROVIDED ON THIS WEB SITE OR IN ANY EVENT TRANSCRIPT. USERS ARE ADVISED TO REVIEW THE APPLICABLE COMPANY&#146;S CONFERENCE CALL ITSELF AND THE APPLICABLE COMPANY&#146;S SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&copy; 2012 Thomson Reuters. All Rights Reserved. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9 </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="28%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">THOMSON REUTERS STREETEVENTS | <U>www.streetevents.com</U> | <U>Contact Us</U></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ROWSPAN="2" ALIGN="right">


<IMG SRC="g451575ex99_1footer.jpg" ALT="LOGO">
</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&copy; 2012 Thomson Reuters. All rights reserved. Republication or
redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. &#145;Thomson Reuters&#146; and the Thomson Reuters logo are registered trademarks of Thomson
Reuters and its affiliated companies.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD></TR></TABLE>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g451575ex99_1footer.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g451575ex99_1footer.jpg
M_]C_X``02D9)1@`!`@$!+`$L``#_X0C/17AI9@``34T`*@````@`!P$2``,`
M```!``$```$:``4````!````8@$;``4````!````:@$H``,````!``(```$Q
M``(````4````<@$R``(````4````AH=I``0````!````G````,@```$L````
M`0```2P````!061O8F4@4&AO=&]S:&]P(#<N,``R,#$R.C$R.C$P(#`S.C0W
M.C0X``````.@`0`#`````?__``"@`@`$`````0```,B@`P`$`````0```"T`
M````````!@$#``,````!``8```$:``4````!```!%@$;``4````!```!'@$H
M``,````!``(```(!``0````!```!)@("``0````!```'H0````````!(````
M`0```$@````!_]C_X``02D9)1@`!`@$`2`!(``#_[0`,061O8F5?0TT``O_N
M``Y!9&]B90!D@`````'_VP"$``P("`@)"`P)"0P1"PH+$14/#`P/%1@3$Q43
M$Q@1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P!#0L+#0X-
M$`X.$!0.#@X4%`X.#@X4$0P,#`P,$1$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#/_``!$(`!T`@`,!(@`"$0$#$0'_W0`$``C_Q`$_```!
M!0$!`0$!`0`````````#``$"!`4&!P@)"@L!``$%`0$!`0$!``````````$`
M`@,$!08'"`D*"Q```00!`P($`@4'!@@%`PPS`0`"$0,$(1(Q!4%181,B<8$R
M!A21H;%"(R054L%B,S1R@M%#!R624_#A\6-S-1:BLH,F1)-49$7"HW0V%])5
MXF7RLX3#TW7C\T8GE*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8W1U=G=X>7
MI[?'U^?W$0`"`@$"!`0#!`4&!P<&!34!``(1`R$Q$@1!46%Q(A,%,H&1%*&Q
M0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:BLH,')C7"TD235*,79$55-G1EXO*S
MA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_
MV@`,`P$``A$#$0`_`/3+\D[C31[GP18]I#O2.TOK?;5NWNW(5EWIU%UKRX[0
M7$ES`36SU][&5!]E>_\`PC/^K6?@7'(>^\N;:7OL<;14Q@(J>*L9MF][;G.Q
MWN]3U&^S_A%H'&?DW$EY937$`3+G:/W&?W/;_P`(J?'+)J!N?2#\O#(?XOR?
M.VI8XXY<)/RCU5\W%'_G?.C^W&NP@O,&PR='L)%;7'']7V-P_P!([]']H^G_
M`&U<QLEE[)T;8V/5JW!SF.(GT[-GYRS<CIM()K_G&$-K>Q\.&QY#0S].[9_.
M>G<S_#;Z?T?\\@=(R7,Z@S'ML:+,BC<^O8TO?96XU.R;LFC=2YUC6?0_P?T/
MYQ*&2<9B,MI'O_@_])=+%">,RAO`7MK^]_T/F=])9O6\W/P::[L2NFQKK&56
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M;57ZAO\`0#7//I@'(^Q^LZQC'O<S9^F]C%2/UKRW44&K'K<^ZR]@N;ZMM+VX
MX9^FQVXU%F38Q[[?3_FOT;ZK?^#24].DL>WKEU5>2\TM/V;,Q\3Z1$B_[+OL
M^C[75_:_YM5;.O\`5L>K/LR,?'C!LKQ_T;[#NLM./Z;]OH[O197E>_9ONWU_
MHTE/1)+FL[ZSY>'3CN>S':ZVN^U[K3=2W]"]E3*:V6T>OZMOJ?X6K_B_45EO
M7<UW4ZL6['9A4VBK8<DO:ZPV,;8^NA[:G8WKTO=Z/V9]WK;Z_P#1I*?_T.SN
MP[JLBR38_:YP-EOHN?;5:?5?]G=8/;7TYS?M'I;?TCU9Q\K/>QKZ@"R[:YE@
M!+7!^YS"Q^W]QOJ6>M73Z/\`-^I=[%H9GV:!ZL>OM?Z$;?5G;[_LV_\`PFU!
M8*-P@M]>63N!]4/],S]J]%W\Y]G^@J7MU(\$K%WZ3KPMR6:XCW(40.L:_E_+
M]!:L/JJW.)L>[WESH:7N#0^7;F^QK6_OLJ]/TF(?3,=PRK;@;6TL8*JVG9Z-
MD_I79=+*A[76N^FCV"N6;R35N.[8`&"OTSIF^H7;F;59H]'T6?9]OH[1Z>R-
MNV/;LC\U/QP]43*5"/RQOYF.4SPR`%\0]1KY0MDXM&56*LAF]@>RP-)(]U;F
MW5.]O[EC&N0;NE=/N^T>K2'?:W5OR-7>YU6WT7:._,]-GT5;25IKM!G1.EUY
MAS64Q>7.L!W.VBRP>G=>RG=Z-=]K/;9<ROU'J=71^F4BD58[&?9MGI.;HX>E
M6[&IW/\`IV^E18^MGJJXDDIS1]7ND^E;4ZEU@O#`]UEEECXJ/J8[67VV/NJ]
M"S])3Z5GZ-Z)3T3I=(9LH!-9L<'.+GESKAMR'W.L<YU[[6_3==ZBO))*:5/1
M^FT8-/3ZJ`W$QG,?14"Z&NK?Z]3@[=O]EHWH=O0>EV'=Z;ZW^I9<'U6V5.#[
MH^T%CZ;*WL;=MW6UL_1^I^D_G%HI)*:#^B=,?EMS'TEUS7,>27OVN?6-E-UM
M6_TKKZF_S=UK/54[>D]/NKR:WU2W,>VW(AS@7/8*VUV!S7;JWU^A5L]/]Q7$
MDE-+]C=/+-ME;KOT5N.3=8^UQJO+7WU/?<][WL?L;]-1_8G3C=5<^MUCJ-AJ
M;998]C75C95:*++'4^M6W_#[/55]))3_`/_9_^T-B%!H;W1O<VAO<"`S+C``
M.$))300E```````0`````````````````````#A"24T#[0``````$`$L````
M`0`!`2P````!``$X0DE-!"8```````X`````````````/X```#A"24T$#0``
M````!````'@X0DE-!!D```````0````>.$))30/S```````)```````````!
M`#A"24T$"@```````0``.$))32<0```````*``$``````````3A"24T#]0``
M````2``O9F8``0!L9F8`!@```````0`O9F8``0"AF9H`!@```````0`R````
M`0!:````!@```````0`U`````0`M````!@```````3A"24T#^```````<```
M_____________________________P/H`````/______________________
M______\#Z`````#_____________________________`^@`````________
M_____________________P/H```X0DE-!`````````(``#A"24T$`@``````
M`@``.$))300(```````0`````0```D````)``````#A"24T$'@``````!```
M```X0DE-!!H``````TD````&```````````````M````R`````H`50!N`'0`
M:0!T`&P`90!D`"T`,0````$``````````````````````````0``````````
M````R````"T``````````````````````0`````````````````````````0
M`````0```````&YU;&P````"````!F)O=6YD<T]B:F,````!````````4F-T
M,0````0`````5&]P(&QO;F<``````````$QE9G1L;VYG``````````!"=&]M
M;&]N9P```"T`````4F=H=&QO;F<```#(````!G-L:6-E<U9L3',````!3V)J
M8P````$```````5S;&EC90```!(````'<VQI8V5)1&QO;F<`````````!V=R
M;W5P241L;VYG``````````9O<FEG:6YE;G5M````#$53;&EC94]R:6=I;@``
M``UA=71O1V5N97)A=&5D`````%1Y<&5E;G5M````"D53;&EC951Y<&4`````
M26UG(`````9B;W5N9'-/8FIC`````0```````%)C=#$````$`````%1O<"!L
M;VYG``````````!,969T;&]N9P``````````0G1O;6QO;F<````M`````%)G
M:'1L;VYG````R`````-U<FQ415A4`````0```````&YU;&Q415A4`````0``
M`````$US9V5415A4`````0``````!F%L=%1A9U1%6%0````!```````.8V5L
M;%1E>'1)<TA434QB;V]L`0````AC96QL5&5X=%1%6%0````!```````):&]R
M>D%L:6=N96YU;0````]%4VQI8V5(;W)Z06QI9VX````'9&5F875L=`````EV
M97)T06QI9VYE;G5M````#T53;&EC959E<G1!;&EG;@````=D969A=6QT````
M"V)G0V]L;W)4>7!E96YU;0```!%%4VQI8V5"1T-O;&]R5'EP90````!.;VYE
M````"71O<$]U='-E=&QO;F<`````````"FQE9G1/=71S971L;VYG````````
M``QB;W1T;VU/=71S971L;VYG``````````MR:6=H=$]U='-E=&QO;F<`````
M`#A"24T$$0```````0$`.$))3004```````$`````SA"24T$#``````'O0``
M``$```"`````'0```8```"N````'H0`8``'_V/_@`!!*1DE&``$"`0!(`$@`
M`/_M``Q!9&]B95]#30`"_^X`#D%D;V)E`&2``````?_;`(0`#`@("`D(#`D)
M#!$+"@L1%0\,#`\5&!,3%1,3&!$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`$-"PL-#@T0#@X0%`X.#A04#@X.#A01#`P,#`P1$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,_\``$0@`'0"``P$B``(1
M`0,1`?_=``0`"/_$`3\```$%`0$!`0$!``````````,``0($!08'"`D*"P$`
M`04!`0$!`0$``````````0`"`P0%!@<("0H+$``!!`$#`@0"!0<&"`4###,!
M``(1`P0A$C$%05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U
M%J*R@R9$DU1D1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?56
M9G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1``("`0($!`,$!08'!P8%-0$``A$#
M(3$2!$%187$B$P4R@9$4H;%"(\%2T?`S)&+A<H*20U,58W,T\24&%J*R@P<F
M-<+21)-4HQ=D154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:F
MML;6YO8G-T=79W>'EZ>WQ__:``P#`0`"$0,1`#\`],OR3N--'N?!%CVD.]([
M2^M]M6[>[<A67>G476O+CM!<27,!-;/7WL94'V5[_P#",_ZM9^!<<A[[RYMI
M>^QQM%3&`BIXJQFV;WMN<['>[U/4;[/^$6@<9^3<27EE-<0!,N=H_<9_<]O_
M``BI\<LFH&Y](/R\,A_B_)\[:ECCCEPD_*/57S<4?^=\Z/[<:[""\P;#)T>P
MD5M<<?U?8W#_`$COT?VCZ?\`;5S&R67LG1MC8]6K<'.8XB?3LV?G+-R.FT@F
MO^<80VM['PX;'D-#/T[MG\YZ=S/\-OI_1_SR!TC)<SJ#,>VQHLR*-SZ]C2]]
ME;C4[)NR:-U+G6-9]#_!_0_G$H9)QF(RVD>_^#_TETL4)XS*&\!>VO[W_0^9
MWTEF];S<_!IKNQ*Z;&NL958+G.:0;;*\>DL]-EGM:^W=:J65]9;L2S)QK:`[
M*QW8S&!GJ&MSK_2]7=?Z6REM;K'^GZO\XKC3=])8E?7,TY=9LQJVX&1E6X55
M@L)NWU&YGK/JV>GZ5EN+:S;ZOJ,]CU7P/K:[,=TVD8NW(R]_VVO=/H;6/LHY
M:W?]M<S]5W;-]/Z1)3T:2YRCZRY[\9SK<:IF8^RBFO#+[&/J?>2!]N]:EFVI
MFW^>QVW5Y/IO]!2L^LV7C.8S*Q&S3DOHZ@^IY<VNMM=61]MKEC7OI:S)H=?O
M_F?TO[B2GH4EBY'7;ZNB?M)M5?J&_P!`-<\^F`<C['ZSK&,>]S-GZ;V,5(_6
MO+=10:L>MS[K+V"YOJVTO;CAGZ;';C469-C'OM]/^:_1OJM_X-)3TZ2Q[>N7
M55Y+S2T_9LS'Q/I$2+_LN^SZ/M=7]K_FU5LZ_P!6QZL^S(Q\>,&RO'_1OL.Z
MRTX_IOV^CN]%E>5[]F^[?7^C24]$DN:SOK/EX=..Y[,=KK:[[7NM-U+?T+V5
M,IK9;1Z_JV^I_A:O^+]166]=S7=3JQ;L=F%3:*MAR2]KK#8QMCZZ'MJ=C>O2
M]WH_9GW>MOK_`-&DI__0[.[#NJR+)-C]KG`V6^BY]M5I]5_V=U@]M?3G-^T>
MEM_2/5G'RL][&OJ`++MKF6`$M<'[G,+'[?W&^I9ZU=/H_P`WZEWL6AF?9H'J
MQZ^U_H1M]6=OO^S;_P#";4%@HW""WUY9.X'U0_TS/VKT7?SGV?Z"I>W4CP2L
M7?I.O"W)9KB/<A1`ZQK^7\OT%JP^JK<XFQ[O>7.AI>X-#Y=N;[&M;^^RKT_2
M8A],QW#*MN!M;2Q@JK:=GHV3^E=ETLJ'M=:[Z:/8*Y9O)-6X[M@`8*_3.F;Z
MA=N9M5FCT?19]GV^CM'I[(V[8]NR/S4_'#U1,I4(_+&_F8Y3/#(`7Q#U&OE"
MV3BT958JR&;V![+`TDCW5N;=4[V_N6,:Y!NZ5T^[[1ZM(=]K=6_(U=[G5;?1
M=H[\STV?15M)6FNT&=$Z77F'-93%Y<ZP'<[:++!Z=U[*=WHUWVL]MES*_4>I
MU='Z92*15CL9]FV>DYNCAZ5;L:G<_P"G;Z5%CZV>JKB22G-'U>Z3Z5M3J76"
M\,#W6666/BH^ICM9?;8^ZKT+/TE/I6?HWHE/1.ETAFR@$UFQP<XN>7.N&W(?
M<ZQSG7OM;]-UWJ*\DDII4]'Z;1@T]/JH#<3&<Q]%0+H:ZM_KU.#MV_V6C>AV
M]!Z78=WIOK?ZEEP?5;94X/NC[06/ILK>QMVW=;6S]'ZGZ3^<6BDDIH/Z)TQ^
M6W,?277-<QY)>_:Y]8V4W6U;_2NOJ;_-W6L]53MZ3T^ZO)K?5+<Q[;<B'.!<
M]@K;78'-=NK?7Z%6ST_W%<224TOV-T\LVV5NN_16XY-UC[7&J\M??4]]SWO>
MQ^QOTU']B=.-U5SZW6.HV&IMEECV-=6-E5HHLL=3ZU;?\/L]57TDE/\`_]D`
M.$))300A``````!5`````0$````/`$$`9`!O`&(`90`@`%``:`!O`'0`;P!S
M`&@`;P!P````$P!!`&0`;P!B`&4`(`!0`&@`;P!T`&\`<P!H`&\`<``@`#<`
M+@`P`````0`X0DE-!`8```````<`"`````$!`/_A$DAH='1P.B\O;G,N861O
M8F4N8V]M+WAA<"\Q+C`O`#P_>'!A8VME="!B96=I;CTG[[N_)R!I9#TG5S5-
M,$UP0V5H:4AZ<F53>DY48WIK8SED)S\^"CP_861O8F4M>&%P+69I;'1E<G,@
M97-C/2)#4B(_/@H\>#IX87!M971A('AM;&YS.G@])V%D;V)E.FYS.FUE=&$O
M)R!X.GAA<'1K/2=835`@=&]O;&MI="`R+C@N,BTS,RP@9G)A;65W;W)K(#$N
M-2<^"CQR9&8Z4D1&('AM;&YS.G)D9CTG:'1T<#HO+W=W=RYW,RYO<F<O,3DY
M.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R<@>&UL;G,Z:5@])VAT='`Z+R]N<RYA
M9&]B92YC;VTO:5@O,2XP+R<^"@H@/')D9CI$97-C<FEP=&EO;B!A8F]U=#TG
M=75I9#HS-C-A8F1B,RTT,C,Y+3$Q93(M.34Y9"UD.#%C-F5D9&$Q93@G"B`@
M>&UL;G,Z>&%P34T])VAT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]M;2\G
M/@H@(#QX87!-33I$;V-U;65N=$E$/F%D;V)E.F1O8VED.G!H;W1O<VAO<#HS
M-C-A8F1B,2TT,C,Y+3$Q93(M.34Y9"UD.#%C-F5D9&$Q93@\+WAA<$U-.D1O
M8W5M96YT240^"B`\+W)D9CI$97-C<FEP=&EO;CX*"CPO<F1F.E)$1CX*/"]X
M.GAA<&UE=&$^"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H\/WAP86-K970@96YD/2=W)S\^_^X`#D%D;V)E`&1`````
M`?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$!`0$!`@(!`@(#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M_\``$0@`+0#(`P$1``(1`0,1`?_=``0`&?_$`:(````&`@,!````````````
M``<(!@4$"0,*`@$`"P$```8#`0$!````````````!@4$`P<""`$)``H+$``"
M`0,$`0,#`@,#`P(&"74!`@,$$042!B$'$R(`"#$403(C%0E10A9A)#,74G&!
M&&*1)4.AL?`F-'(*&<'1-2?A4S:"\9*B1%1S148W1V,H5597&K+"TN+R9(-T
MDX1EH[/#T^,I.&;S=2HY.DA)2EA96F=H:6IV=WAY>H6&AXB)BI25EI>8F9JD
MI::GJ*FJM+6VM[BYNL3%QL?(R<K4U=;7V-G:Y.7FY^CIZO3U]O?X^?H1``(!
M`P($!`,%!`0$!@8%;0$"`Q$$(1(%,08`(A-!40<R811Q"$*!(Y$54J%B%C,)
ML23!T4-R\!?A@C0EDE,88T3QHK(F-1E4-D5D)PIS@Y-&=,+2XO)59756-X2%
MH[/#T^/S*1J4I+3$U.3TE:6UQ=7E]2A'5V8X=H:6IK;&UN;V9W>'EZ>WQ]?G
M]TA8:'B(F*BXR-CH^#E)66EYB9FIN<G9Z?DJ.DI::GJ*FJJZRMKJ^O_:``P#
M`0`"$0,1`#\`WZLGD\?AL?69;+5M-CL;CZ>6KKJZLE2"FI::%2\LTTKD*B(H
M]H-TW3;=DV^\W;=[Z*UVRWC+RRRL$C1!Q9F8@`#YGY=*K*RO-RN[:PL+9YKV
M9PB(@+,S$T``&23T%$796>RN_MJ8S;&UZ3<75NX=J9'<%3VC0YN!\7CZJEE1
M:;'F!8F$DE2A+#U6L"25TD$#?UYW6[YLY>LMDY8%][>7NW27+[U%=0FVB==6
MB(1BID5U`)E5P%U?"=)Z%S\K;7:<N[U<;OOS6G.]K?)`NUO;R":1&'?+KPJ:
M#VE&&HXI4'&*L\F4P3;-S':]='N+=$V6SVW=R[,I*7&9"GP&*K(:S[?'STU+
MDL74)04ZB&5Y=35"NPTGZ>XXEM=RWSE*X]O.8O?"\EYMWE[J^LMSVFW%J\-C
M!.CK%#-;));E84TPN\DGC7(9Z`DT!E`T5ANR<Q;?R%"=HLEB@GMKQVD1[B5&
M74ZLT<JES5U5*",J#4#/43&]AXS=&Y^N=R8/M#&T.RMX8K=%#AMD93`PX_+[
MWS.)KQ2MEL=7Y5:3,T<6+\+#[<1*)A*C$<@>Q1MW/6U;_P`S\@;OM?N;!'RY
MNMA=I;[9+!'%<[A<1.NJX0S(ERHMECE5HHT1&+:S50*.WO*5]L>Q<X;1NO(T
MS\R;=<VSSWJ3F2*RAE0D1.D+-"S3%E(D+L5TLM*U(<]O]IRTV+:L[9Q>.ZIK
MJW=N2V[MO'YO<&-F?<%)%6"'%5]&T4@]==#(A*?5"06"A@/>^2/=#=+K9[>X
M]V^7[;E+?;K=)K2TMI[R-S=!&I&\3$1U,@^%174*,,.HZ1;WR1`;OP^1-PFW
MZQAV^*XN98;>4"W8I65'J.$9![N!`-"=)/0P@@@$$$$7!'((/T(/Y!]S-U'H
M((J.'7?OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO_0W-.U
MMS]I;@[>P/66,V+MK>?0^>HYL)VEE),C3.^!CJ:&KJZ^;.3I5++A):"."$4T
M)0M4O,#<:>,5O<S=_<'FKW-V[VR@Y$VS=O8F^L`N[W,LH/A,SRB2-RD@\%HU
M2.2-76KL#0C!&0_M_L_(FU<@;USI?<UWFV^Z]G*LVUQ+&P\<JT:HL*E:3!R[
MF1P=,:K0Y;I<;`Q5%@<3AL3CML;CZ\VIM^JRNP=O[(J#2Y3!;GIJ]2V.W/53
M8\U<\=%4JKL'=P5#G7R1[/\`D^VCVVPY6V]>6-UY>V';+V]V>TVP.ES:7\)&
MF&]G:(/2W<*TL,K.!^H=1-1T$^9KZ?==QW7<;G>K3=M\O$BW"XO`KPSVTBFL
MMNHDT`R+4`J%-2HT\#T&VYNQ:W`/M_'[=ERU,,+MW)8/([3ZSVS2Y;"5-9N;
M-#;6*RNV=TY7[:%LELN>];/CXR9'6X93:WL.WWN%N?+^R[+<V\X$T&VW49L=
MFMHY[&4FX^GC>VNY_#I-M^D2W$*XTK*6!5:]"O9N4;#=WW27=/IF2>^25;K<
M;J2*XC$$!N9(KFVAU%8KT'P8[AZ*&TE2*]%RJNZ:W[3$P[GF;L4];=;=IPFK
MK-DM@?D#NC<5-D:G:4_9'6V/BC2DQNV30Y2*(S1C7.Y$H4@*?<6;ISINT<5K
MN>][8N\V^R;%ND1G>T2VYAFD>X2UFO\`:`HT16B+-&OB##"&1F_4\.LOKR):
MF]NHN7XOW1+ON][80$N_J.7+6!X/KHMMW29B7>ZU0^)X9^`'PZY(Z:L2G]U*
MKK3KWLK:B[VZAQNW)-Y]/]R]S;J@I=YT/;>:>+<.(ZYSR+4^)*K[V6GH!2M>
M5(Z>/4#Q=#M&T[%MT7(G)_.W*W[TY1M;=]PV?<MZN?"G?=KE%FBVYD62BRI)
M6*6)NY65)!2M.C3=GN-^M^=^<.3.86VSGZZOULMWV?9;0O9?NB!7@FW.!M)+
M1E$><R'L+2NHIGH[/QB[#[?WKMW/TW>FW<+L_?&*SU7!C\'0U%-%D:K;`"_P
M_,5^$6HGJL8*IRRQEO3+&H=>&]Y*^PO./N?S7R_NA]W=@M=IYKBO'"6J'3((
M*`J6C+,=`)*QR_Z(O<>L;?>OE3VXY9W_`&S_`%K.8+C<^69[&-WE=&,<=QD2
M11SZ566F"0,HQ*'AT9[W/'4,=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=?_]'82ZW.P,Q5_*;<O5^V>RNY,CO'>,'7^Y>NMV;HQVVJ5=F[MW!E
M-S5^:Q^Z,)FQ)49/(9FITT\=1X:^BBC,3(^HPGE=REMO+@M/>K=N3N6=SWV\
MO[N*VOMKN;B#;E2PO+N:47$MS'-,LMQ'-&RP4>$-`ZLZ:)7IU'Y^N.;-H_X'
MO8.?-[V/EF*QV^6_M=RM+.6\8W5E;PVZVSVTT*F-1;H'<QB2WF?N##2LO5K%
M!#0X%<MBUQ6YMET-#C-O;(VW15NY9FH,OCL)@%R[U&T**F6MJC5T,B?:U$TY
MB:I1&+.HL3F78V%ELUWNEJ^P;IL^W6UA#MEFK;CKBO+2WB:Z:2SAADN'CND-
M8&DF6*69!168`=8*7-S<[P]K?#<;7<KN6YN+NX=;,AH99I_!`NG<1J8Y`?%0
M1EUC9@%!-0&WK[HO;V>IT[`[/QZ[IWCN-CEH*+(U/W&W=FX^I*R8S#;1Q5-!
M046.@IH+R^=HFKFEJ91),X/M?R-[6\N[I:6_.?-^VP;AOE_&9$CDB*6EI!,*
MK!;V3A8T.AJS321&YF=G,DA4A0_S7[C[MMKORER9?26'+MH/"D:,:+B]E4TD
MGNYM4DCLQ&A8EE%NL:)IA5JGI1;_`-@[1H4PTL<'V<\N;QU1MXFJKXVQ^[]N
M*=S[:J/XE152;B.#GJ=M04M7BH'GAKHHZ>!*<#6)/<\\JVFR'9H^6XQ!/>7*
MQ6T1F:*"WO+>.>]MIE5&286YD@5+RVA=TEMD2-;0D%U*>5>9=YD:^\217MHK
M5Q<_IQN9;6>EI,I21&A-PBW,DD%TX2:*1Y)3.3IH03O/HN==F]C5FW.C]E[P
MJMJ[EVIW?M89WLO)XG^\'8.Z6I'W95U^VLKD<3E\%1TLF/B^WIL@]`IC4JC2
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M7TDC@V_-C[Z)]<Y^J/\`<.*^==)\T]O?%^F^>62CQ>[>E=V]U0[DBZ"ZZ63#
MG#[YI-O46TUQ,U9,:JF%!7JQJS5ZRR6T<DCW7NEI3?S#L=T]\L_EOU9\@-];
M@.S]G'KN+J+&[>ZJW3NIJ!ZK9T51N26NR.Q-NYN>$Y#+GS!*_0%N?&Q06&Z5
MX#/7N@+Z]^:7RQ[5^.'Q*V]L_?.W*'N7Y7_(#MK8O^E[/[1HIZ?8W7.Q\OE\
MI%7T.SH#0T60W!_=R&"&%*@(`VHRKKX]^(I3YCKW0X4/>?RB^/?:OR(^-_;_
M`&_A.[,AC_A_V#\E^FNV8M@8S9&?P-?M%,EB:G`;LV[CJZMP.1@BR*Q5-/+&
M1J$15P1(=&NO=%BVW_-8[97^7[EZC+&DKOG+39->O-OXIL90P5>XESFVAOW`
M=QTNUX(S23[>@Z[J!62R*HHS50F]D.CW[KW2Z[-^5ORQ'4'P;W=4]D;BZHZE
M[.Z>AW5W[\G-D=&MW#D,'OYJ*$XK%Y39F-@GI-M[8S!US3UZPE(.;<+;W[KW
M0N;R^1O>.+Z=^+77G1_R9Z^[]W_\KNZ<CU]@_E"NR,/C\%L_:E#@*_<V6J5V
M-ALSD,;E-UX:AQ,D*QS24_[DH,L*D!6]U[IPH.Z_E+\=>Y^W/C=W#W!@^]6R
M7Q-[$^1?47:<77^-V+N7:^8V8N7QM5MS=.`Q=;6X++T)JZ-:FFFBL_[>F0'R
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M4T8&N;4\UO63[]U[HH/=G=_S/QOQ*^+'RKV9\K:C`OW'C/C[L3<.Q1U'LBOQ
MZ[I[$R"87<>^H,W6@5D<_ER"S)0BG6GU4X5657)%@IU!?/KW0@_+3O#Y#?%?
M<WQ=Z0WS\PLU14O8E7W#N7L#O["_'[#[BWA+C=OX_&/LW:6-ZQP"9ZGDIH:V
ML*5%53JTQ5_*P5(F#5Z]TQ=Y_+7L[97Q5Z#W;UO\P,QE*?L?Y)U&P=X?(C?O
M1-'L;*;<V>@K!DJ>;KO/8N@ACI<'/``M88`)XR#JM=O?OMZ]T^].?+#Y3YIO
MF#LKIGM#`?..#JSH^CWQT_V_C.MHMH45?VW6U4E-/U571X7(KMO<==38]#6P
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M#@DS/L/O7M6SK-L\VW*MG;K*RQEC;301P,@N`8[LH)K:)FE,%W$ZQ31".-(@
M>XQ#N/LIOF[3_O*SNUEM9A#^O$AN;=YKA6:W@+VP=HKZ95'BVSQDQR:R\IK0
M1\-OC=_:&X3N+<V-I]L;6VKF,K2X3`8_,5V2%#48S$4U3NC/]CYC"F"FP67Q
M>U]P2?PRAC^X\>1@2HCG(8>RNTYQYIY_YAN-Z*6]KR]MHN(DMPTDRVUQ$MN;
MZ;<[JVDC$%Q#9W$L=I;P&4&4B83`J5Z<W'ECE[DS9H=EVN\:_P!\OXHGFGDM
MTC$JO*QLH-N@GUO-$]S;H;JX;PB8M<+1#AU,[?Z\H.PMN;IQ]3UELW>C=HY3
M:V,SRTFXZC;.?R?56(GBDQNY,W/6)'5U-?A'GD_;8:$72IO:PK[@[!MV];5O
ML47(FT[YN&_W.WQRB*]-M?ML45`FX7$\KK,3:R!B-&E>XU+.'U,<C<U;CRIO
M&QW=ESWNFU'8[:ZE@8P+<01;K(I#VT"#7$L=P`*L022-0'`]`OT?LOM>3Y8;
MCW)E>KNH&Z5V]MB3:?7/8^VFP6>W##BL(L-/@:(;B66ISQRYC#)7)*RJOXL+
M>R7VVV[G6;WXWB^3DG9F]KK2U>UL=QB2SED6*!!';""[B=[EI6C)CN5F8@`D
M*J><@^XN^>WR_=_V#:['GKF(>Z-Y?"\W/;+@W$-JT\Y9IY3;,JP:`U&@=%#-
MYDCJR_WF1UAYT63*?'"DR7RWVO\`*G^]-9%6;;Z5SW3J[/\`L:9J&J@SFZ*/
M<KYPY"XJHZB!J)8A%RA!)^OOW7NH/6WQ@H.N^\?DGW3'NVNS$_R(FVC//MVK
MQF-2BVD^U-N?P!6Q]6D/WE<:\?NN)F95/"BWOW7NBM4W\L;$8OX_=8]4;=[M
MWQMCL;I/MG>'<G57=&%QN"ASFW-S[PS63RN0Q]5@YJ27#Y3`5%-DFI9Z>1+S
M0J+L#[V232O7NE=L?X"9>+(=X]A]U]\[J[I[Q[HZ5W#T-%O_`">`P.WL-U[L
M+/X^K@GQ^S-F8:"'$4;RY*I6LG=PSS2)I)"NX.OLZ]URV]_+.Z2PM/LO/U-7
ME<KVQL?XO5GQAQ?852M.J3X>JVW)MB+>U;MI4_A-3O.BQDGBBJF4LL'[?Z?>
MZGUZ]T^2_$OOC9_371_4?1?RORW5])U'L&GV+F*JMZNV!O6BWZE+3QTU/F,G
MC]P8VH;&5U/&ATI2R1Q'5RI]Z^WKW06T/\K39N&^/.S>J=O]N[[P':>P>Z\K
M\D-K=[8RDP<.>Q/<N>9AFLO1[:-$VW8-M9&E<TSXQ8A"(#P0_J]^Z]TM]@_`
MO<$.XNV.TN\^_P#=7=W=W9/3.X>B<1O3(;>P&VL#USL+/TU8M31[0V=AJ>/&
M4]34Y*J^[J99"S32AAPKL#[KW08=V?RGMB]Q=4?&#8S]H;FVWO+XU[>VMLVG
M[(Q^(P\N3WULW;TN.JIML[CQLD(H1C:BMQPFA2,`4SNQ7Z^_=>Z.=\JOC70_
M)_X[[GZ`K=UY'9])N.GVY#_>7&4='75U&=NY7&Y2)DI*Y'I9!4MC@CAAPKFW
M/OW7ND/#\,L#MWY(;.^1?7>ZZG8=?%UK/U5W!LW#83$1[;[CVU!#"=N5>;CC
M@AJ,5GMM5R/+3U=,RR,C")KQ@@^Z]T"WQX^#GR%^-M3L_9NR/F'D)N@=F[LR
M^8H>KLEU#L&IRM5MW+9K*9N?;55OB2C?-@25638M41E)./3IO[WCKW35O#^7
M%O22N[LVSU%\H]Y]3='_`"-W/EMV=K]8T>SMG[AK%R6Z+1[Q38N[LQCYLMM6
MFW)`")57RE&8E3]![]C\^O=#IW;\']F=J?'[J#X[;>W-E]@;1Z;W;U+N/;U7
M04M#EJZHHNI\GC\A18BK_B,;PD9A:#1/,JAU+LR6-K>!(((X]>ZY?*CXE;I[
MS[`Z8[AZO[BK>E>V.E!O*CV_N--IX+>^,K,/OK&TN.S5'6X#<$<E$\ZQ4@$4
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MQ5%68+:N&RKTL69DPO\`%$I8HU))C$%-G:IWB2PJ`65@Q8>\:/>'VHVM^:++
MW[L[+=]PYOY=L6:WVVS8TOIDU>`I4!GJ&D(81TUH2&KP.0/MG[J;[!RK>^R<
MVZV%AR?O=PZSW4\>KP%F\+6:C^(V\85FKX;48$`'HMF'Z&UYC8^0VGUUM':F
MT.R]P9CN'OGJ/M&>7<>^:W<F+C+8:JVIAJJ8U5/+33AFADB&L3.GE'U]QKRO
MR!NL%GR9NO+W)>W;=RKN\K;MO6Q[B?J=P\9"[@V>NK+0$K"H"E7<";%5ZE+>
MO=!9[?F>UWOGS<[SFW9+&/9]@W;;`+:P6UE?]=+MU&F164@-K.DH"8S7I5[.
MZSV974?6.-KZ_?6.'9>]]]9#.[2[VVM%O3=6X=J1B>JK^O7W"RLNR=NQ2TJ3
MTT)<+.4$=KC2;<GV.U;K+[7P;CO6Z07/,M]N<TFW[UMXGO9K.-&=]M+J&CMK
M6(HLRNSJ'(1T&I=!+.9N;^8+6?G2]M[/:Y3L6W;=%;WFR7C65K#=51(MP%N#
M6]N65WCD8K5=1<FAU`U^S,/3M1;3R<V0R6\7.Z=YTL65PV%BVOATH:R/)T2-
MN7"0%(,G18ZBP\5!3U,BNSL8F6ZD-[E'E6>TD7DB_MIMXWVN][G:O/;V:V%O
M$3XL4AW.U72LL=L(?IHKA@2\@1^+]0;OFX2(V]V$%I;[="-OLF\*6=KJ4E#$
MX^FG>K1O(9FGDC4@`>(#D4Z"[L/.UF-I]GY9-BKV_N/?4V:ZHW#OSKH210;0
MVEE,J82)FBFJ5IC3)DG=B;?O4[FX%A["W.T5[MHY0W6\]NTYSYUW"2ZV2YW'
M:D,0L=IN92S)(4:0141XZZJ()$D?4H(!&7*-M87_`._[=><DY<Y>VU8=SM[/
M<2&-W>QQC3H!5=>IHPH'\,B``Y/0H=!?'S9?QVVUF=M;,JLW71;@W#5[ERM;
MG:]JVIFR%7''#HA4!8:6FAAB`5$`N;DDD^Y8]F/9O8/9/EFYY:Y?W*]NK>:X
M:9VN7#'613M50%7M`U4^-AJ.3T$O=CW<YE]X-ZVW>^98+6*:TLTMHU@C$:B-
M"35N)9B2223@4`H!T.WN7^HLZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z__]3?X]^Z]T"&9_T)?Z=-J?QC^$_Z;_[I9;^['D_B/\0_NQ]PG\0M
MX_\`<1Y/+_F_-_E.G5X_3J]PQNW^M7_KX<K_`+RK_KN?N>;Z6GC5^AUMXE=/
MZ>G7KIJQJU?BIU).W?ZXW^M?S!^[_%_UL_WE#]53PM'U>@^%6OZWP\='9PUY
MITZT--V`VR=Q0QYK,0[K?,Y=L-D<]MG;535TU`:M&I(J+"XW=M)BZVD2E#+3
MR5%?3S-?5*BD:"5\I6GN@>0][M[_`)@W$<ZMO=R;:?<]OVTNEM]0#&D=I8[F
ML,EJ(-2QR/>Q7;)JDEB5Z1E%?S<IKS%M4AVV%MB%K%XT=M<W"AI-!U%IIK1W
M1R]"ZI!(@^%&(.H.61CW4>S=N2TU;N==IKMS*+E:*EQFUI-IRY+RC[:7*Y.K
MR\>[:?*@%?MXZ.DEIBH;RN"186WL7,_^NARQ*E]NG]6!LUT)XHX+7Z!K@RV_
MAR7$[W'U23JH<0PPV\D;!G9YT"%72VC['_4G=DEM[#]_?6Q&-WDNOJQ%I.I8
M8TB^D,5?[1II1)6@C3B>D[T9_H8_NOEO]!W\,_NM_>C-?Q+^$_Q3[/\`O'YQ
M_%O'_%/7I\EM/B_8TVT>GV&/N_?ZRW]3]T_UC=']5_WI<>-3ZC5]7J'BZ_J_
M\8K33H\3_0].GMIT=>Z7^N5^_-O_`-='Q_W[]##X?B^%K^GT_I5\+'"M=??6
MNK/0U>YUZC/KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
"_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
